Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 congress, reporting that approximately 80% of participants treated with verekitug achieved clinically meaningful improvements in nasal polyp score (NPS) — the primary structural endpoint for chronic rhinosinusitis with nasal polyps (CRSwNP). The data underscore a growing clinical and commercial interest in anti-inflammatory mechanisms that cross over between pharmaceutical pipelines and the broader functional health category.
Verekitug is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that sits upstream of the type-2 inflammatory cascade. By blocking TSLP signaling, the compound is designed to suppress the eosinophilic inflammation that drives nasal polyp formation and recurrence. The once-every-three-months dosing interval — a quarterly subcutaneous administration — differentiates it from existing biologic options that require more frequent injection schedules, a distinction Upstream Bio has positioned as a meaningful adherence advantage. The VIBRANT Phase 2 trial was a double-blind, placebo-controlled study; full peer-reviewed publication of the complete dataset has not yet been announced.
While verekitug itself sits firmly in the pharmaceutical biologics space, the TSLP pathway is attracting attention from functional ingredient developers exploring botanical and nutritional modulators of the epithelial-cytokine axis. Ingredients such as palmitoylethanolamide (PEA), quercetin, and standardized Boswellia serrata extracts are increasingly studied for structure-function claims related to upper-airway comfort and normal inflammatory response — categories where operators are watching late-stage pharma data for mechanistic validation. The global nasal health supplement segment, while not yet independently sized by major analysts, sits within the broader respiratory health supplement market, which several industry trackers place on a strong post-pandemic growth trajectory. Distribution has expanded notably into DTC e-commerce and specialty pharmacy channels, mirroring trends across the immune health and respiratory wellness supplement categories.
For finished-formulation brands and co-manufacturing partners active in anti-inflammatory or respiratory support SKUs, the VIBRANT responder data serve as a useful benchmark for communicating clinical endpoint standards to retail buyers and formulators. The 80% responder threshold — tied to a validated composite score rather than subjective patient-reported outcomes alone — raises the evidentiary bar that savvy consumers and practitioners are beginning to expect from non-pharmaceutical products in adjacent categories as well. Brands holding structure-function claims around nasal comfort or sinus support may find it worthwhile to revisit their substantiation dossiers in light of this emerging clinical comparator landscape.
Upstream Bio has not announced a commercial partnership, white-label licensing, or ingredient supply arrangement; verekitug remains an investigational biologic. Further Phase 3 planning details are anticipated following the EAACI presentation.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.